Epidemiology, Diagnosis, and Management of Clostridium Difficile Infection in Patients with Inflammatory Bowel Disease

Overview

Journal Inflamm Bowel Dis

Publisher Oxford University Press

Specialty Gastroenterology

Date 2016 Apr 28

PMID 27120571

Citations 29

Authors

Krishna Rao

Peter D R Higgins

Affiliations

Soon will be listed here.

Abstract

Clostridium difficile infection (CDI) is a major source of morbidity and mortality for the U.S. health care system and frequently complicates the course of inflammatory bowel disease (IBD). Patients with IBD are more likely to be colonized with C. difficile and develop active infection than the general population. They are also more likely to have severe CDI and develop subsequent complications such as IBD flare, colectomy, or death. Even after successful initial treatment and recovery, recurrent CDI is common. Management of CDI in IBD is fraught with diagnostic and therapeutic challenges because the clinical presentations of CDI and IBD flare have considerable overlap. Fecal microbiota transplantation can be successful in curing recurrent CDI when other treatments have failed, but may also trigger IBD flare and this warrants caution. New experimental treatments including vaccines, monoclonal antibodies, and nontoxigenic strains of C. difficile offer promise but are not yet available for clinicians. A better understanding of the complex relationship between the gut microbiota, CDI, and IBD is needed.

Citing Articles

Inflammatory bowel disease and infection: clinical presentation, diagnosis, and management.

Bai M, Guo H, Zheng X Therap Adv Gastroenterol. 2023; 16:17562848231207280.

PMID: 38034098 PMC: 10685799. DOI: 10.1177/17562848231207280.

The pan-microbiome profiling system Taxa4Meta identifies clinical dysbiotic features and classifies diarrheal disease.

Wu Q, Badu S, So S, Treangen T, Savidge T J Clin Invest. 2023; 134(2).

PMID: 37962956 PMC: 10786686. DOI: 10.1172/JCI170859.

aggravates dextran sulfate solution (DSS)-induced colitis by shaping the gut microbiota and promoting neutrophil recruitment.

Dong D, Su T, Chen W, Wang D, Xue Y, Lu Q Gut Microbes. 2023; 15(1):2192478.

PMID: 36951545 PMC: 10038061. DOI: 10.1080/19490976.2023.2192478.

Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent infection in patients with inflammatory bowel disease.

van Lingen E, Baunwall S, Lieberknecht S, Benech N, Ianiro G, Sokol H Therap Adv Gastroenterol. 2023; 16:17562848231156285.

PMID: 36910163 PMC: 9998411. DOI: 10.1177/17562848231156285.

Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease.

Mosli M, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K Saudi J Gastroenterol. 2022; .

PMID: 36412460 PMC: 10540981. DOI: 10.4103/sjg.sjg_277_22.

References

Clayton E, Rea M, Shanahan F, Quigley E, Kiely B, Hill C . The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol. 2009; 104(5):1162-9. DOI: 10.1038/ajg.2009.4. View

Bacci S, Molbak K, Kjeldsen M, Olsen K . Binary toxin and death after Clostridium difficile infection. Emerg Infect Dis. 2011; 17(6):976-82. PMC: 3358205. DOI: 10.3201/eid/1706.101483. View

Hohmann E, Ananthakrishnan A, Deshpande V . Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. N Engl J Med. 2014; 371(7):668-75. DOI: 10.1056/NEJMcpc1400842. View

Wilcox M . Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect. 2012; 18 Suppl 6:13-20. DOI: 10.1111/1469-0691.12057. View

Koo H, Koo D, Musher D, DuPont H . Antimotility agents for the treatment of Clostridium difficile diarrhea and colitis. Clin Infect Dis. 2009; 48(5):598-605. DOI: 10.1086/596711. View

Thomas C, Stevenson M, Riley T . Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003; 51(6):1339-50. DOI: 10.1093/jac/dkg254. View

Bennet J, Brinkman M . Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989; 1(8630):164. DOI: 10.1016/s0140-6736(89)91183-5. View

Kornbluth A, Sachar D . Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010; 105(3):501-23. DOI: 10.1038/ajg.2009.727. View

Borody T, Warren E, Leis S, Surace R, Ashman O . Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol. 2003; 37(1):42-7. DOI: 10.1097/00004836-200307000-00012. View

10.

Antonopoulos D, Huse S, Morrison H, Schmidt T, Sogin M, Young V . Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun. 2009; 77(6):2367-75. PMC: 2687343. DOI: 10.1128/IAI.01520-08. View

11.

Surawicz C, Brandt L, Binion D, Ananthakrishnan A, Curry S, Gilligan P . Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108(4):478-98. DOI: 10.1038/ajg.2013.4. View

12.

McFarland L . Probiotics for the Primary and Secondary Prevention of C. difficile Infections: A Meta-analysis and Systematic Review. Antibiotics (Basel). 2016; 4(2):160-78. PMC: 4790329. DOI: 10.3390/antibiotics4020160. View

13.

Musher D, Logan N, Mehendiratta V, Melgarejo N, Garud S, Hamill R . Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother. 2007; 59(4):705-10. DOI: 10.1093/jac/dkl553. View

14.

Zhou Y, Burnham C, Hink T, Chen L, Shaikh N, Wollam A . Phenotypic and genotypic analysis of Clostridium difficile isolates: a single-center study. J Clin Microbiol. 2014; 52(12):4260-6. PMC: 4313296. DOI: 10.1128/JCM.02115-14. View

15.

Apisarnthanarak A, Razavi B, Mundy L . Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis. 2002; 35(6):690-6. DOI: 10.1086/342334. View

16.

Goldenberg S, French G . Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect. 2011; 62(5):355-62. DOI: 10.1016/j.jinf.2011.03.001. View

17.

Buffie C, Pamer E . Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013; 13(11):790-801. PMC: 4194195. DOI: 10.1038/nri3535. View

18.

Garrett W, Lord G, Punit S, Lugo-Villarino G, Mazmanian S, Ito S . Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007; 131(1):33-45. PMC: 2169385. DOI: 10.1016/j.cell.2007.08.017. View

19.

Jain T, Croswell C, Urday-Cornejo V, Awali R, Cutright J, Salimnia H . Clostridium Difficile Colonization in Hematopoietic Stem Cell Transplant Recipients: A Prospective Study of the Epidemiology and Outcomes Involving Toxigenic and Nontoxigenic Strains. Biol Blood Marrow Transplant. 2015; 22(1):157-63. DOI: 10.1016/j.bbmt.2015.07.020. View

20.

Epple H . Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig Dis. 2009; 27(4):555-9. DOI: 10.1159/000233297. View